During Human Melanoma Progression AP-1 Binding Pairs are Altered with Loss of c-Jun in Vitro

Pigment Cell Research

Volumn 17, Issue 1, 2004, Pages 74-83

  Yang, Sun ^a   McNulty, Susan ^a   Meyskens Jr , Frank L ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Ap 1; c Jun; JunD; Melanocyte; Melanoma

Indexed keywords

ANTIBODY; ANTISENSE OLIGONUCLEOTIDE; CISPLATIN; DIMER; MUTANT PROTEIN; PROTEIN C FOS; PROTEIN C JUN; PROTEIN FOS; RNA; TAM67 PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR FOSB; TRANSCRIPTION FACTOR FRA 1; TRANSCRIPTION FACTOR JUNB; TRANSCRIPTION FACTOR JUND; UNCLASSIFIED DRUG;

A375 MELANOMA CELL; ARTICLE; C81 46A MELANOMA CELL; C83 2C MELANOMA CELL; COLONY FORMATION; COMPLEX FORMATION; CONTROLLED STUDY; GEL MOBILITY SHIFT ASSAY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; MELANOCYTE; MELANOMA; MELANOMA CELL; METASTASIS; NEWBORN; PROTEIN BINDING; PROTEIN FAMILY; TUMOR GROWTH; W1205 MELANOMA CELL; W3211 MELANOMA CELL; WESTERN BLOTTING;

CELLS, CULTURED; DNA-BINDING PROTEINS; HUMANS; MELANOCYTES; MELANOMA; NUCLEAR PROTEINS; OLIGORIBONUCLEOTIDES, ANTISENSE; PROMOTER REGIONS (GENETICS); PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-JUN; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTOR AP-1; TRANSCRIPTION FACTORS;

EID: 0842348917     PISSN: 08935785     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1600-0749.2003.00114.x     Document Type: Article

References (29)

1. Kleeberg UR. Wishful thinking, unicentric empiricism and the everyday world of the medical melanomologist. Melanoma Res 1997;7(Suppl. 2):S143-S149
2. Vogt PK. Fortuitous convergences: the beginnings of JUN. Nat Rev/Cancer 2002;2:465-469
3. Shaulian E, Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol 2002;4:E131-E136
4. Angel P, Szabowski A, Schorpp-Kistner M. Function and regulation of AP-1 subunits in skin physiology and pathology. Oncogene 2001;20:2413-2423
5. Fan M, Goodwin ME, Birrer MJ, Chambers TC. The c-Jun NH(2)-terminal protein kinase/AP-1 pathway is required for efficient apoptosis induced by vinblastine. Cancer Res 2001;61:4450-4458
6. Schadendorf D, Kern MA, Artuc M, Pahl HL, Rosenbach T, Fichtner I, Nurnberg W, Stuting S, von Stebut E, Worm M, Makki A, Jurgovsky K, Kolde G, Henz BM. Treatment of melanoma cells with the synthetic retinoid CD437 induces apoptosis via activation of AP-1 in vitro, and causes growth inhibition in xenografts in vivo. J Cell Biol 1996;135:1889-1898
7. Rabo YB, Shoshan MC, Linder S, Hansson J. Different mechanisms are responsible for c-jun mRNA induction by cisplatin and ultraviolet light. Int J Cancer 1996;65:821-826
8. Yamanishi DT, Buckmeier JA, Meyskens FL Jr. Expression of c-Jun, JunB, and c-Fos pro-oncogenes in human primary melanocytes and metastatic melanomas. J Invest Dermatol 1991;97:349-353
9. Madireddi MT, Dent P, Fisher PB. AP-1 and C/EBP transcription factors contribute to mda-7 gene promoter activity during human melanoma differentiation. J Cell Physiol 2000;185:36-46
10. Meyskens FL Jr, McNulty SE, Buckmeier JA, Tohidian NB, Spillane TJ, Kahlon RS, Gonzalez RI. Aberrant redox regulation in human metastatic melanoma cells compared to normal melanocytes. Free Radic Biol Med 2001;31:799-808
11. Schaider H, Oka M, Bogenrieder T, Nesbit M, Satyamoorthy K, Berking C, Matsushima K, Herlyn M. Differential response of primary and metastatic melanomas to neutrophils attracted by IL-8. Int J Cancer 2003;103:335-343
12. Yohem KH, Bregman MD, Meyskens FL Jr. Effect of tumor colony definition on ionizing relation survival curves of melanoma-colony forming cells. Int J Radiat Oncol Biol Phys 1987;13:1725-1733
13. Harant H, de Martin R, Andrew PJ, Foglar E, Dittrich C, Lindley IJ. Synergistic activation of interleukin-8 gene transcription by all-trans-retinoic acid and tumor necrosis factor-a involves the transcription factor NF-kappaB. J Biol Chem 1996;271:26954-26961
14. Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA, Struhl K. Current Protocols in Molecular Biology. John Wiley and Sons, 1999
15. Urakami S, Tsuchiya H, Orimoto K, Kobayashi T, Igawa M, Hino O. Overexpression of members of the AP-1 transcriptional factor family from an early stage of renal carcinogenesis and inhibition of cell growth by AP-1 gene antisense oligonucleotides in the Tsc2 gene mutant (Eker) rat model. Biochem Biophys Res Commun 1997;241:24-30
16. Brown PH, Chen TK, Birrer MJ. Mechanism of action of a dominant-negative mutant of c-Jun. Oncogene 1994;9:791-799
17. Huang F, Adelman J, Jiang H, Goldstein NI, Fisher PB. Differentiation induction subtraction hybridization (DISH): a strategy for cloning genes displaying differential expression during growth arrest and terminal differentiation. Gene 1999;236:125-131
18. Thompson FH, Emerson J, Olson S, Weinstein R, Leavitt SA, Leong SP, Emerson S, Trent JM, Nelson MA, Salmon SE, Taetle R. Cytogenetics of 158 patients with regional or disseminated melanoma. Subset analysis of near-diploid and simple karyotypes. Cancer Genet Cytogenet 1995;83:93-104
19. Powell MB, Rosenberg RK, Graham MJ, Birch ML, Yamanishi DT, Buckmeier JA, Meyskens FL Jr. Protein kinase C beta expression in melanoma cells and melanocytes: differential expression correlates with biological responses to 12-O-tetradecanoylphorbol 13-acetate. J Cancer Res Clin Oncol 1993;119:199-206
20. Yamanishi DT, Graham M, Buckmeier JA, Meyskens FL Jr. The differential expression of protein kinase C genes in normal human neonatal melanocytes and metastatic melanomas. Carcinogenesis 1991;12:105-109
21. Kaneki M, Kharbanda S, Pandey P, Yoshida K, Takekawa M, Liou JR, Stone R, Kufe D. Functional role for protein kinase C beta as a regulator of stress-activated protein kinase activation and monocytic differentiation of myeloid leukemia cells. Mol Cell Biol 1999;19:461-470
22. Verheij M, Bose R, Lin XH, Yao B, Jarvis WD, Grant S, Birrer MJ, Szabo E, Zon LI, Kyriakis JM, Haimovitz-Friedman A, Fuks Z, Kolesnick RN. Requirement for ceramide-initiated SAPK/JNK signaling in stress-induced apoptosis. Nature 1996;380:75-79
23. Kolbus A, Herr I, Schreiber M, Debatin KM, Wagner EF, Angel P. c-Jun-dependent CD95-L expression is a rate-limiting step in the induction of apoptosis by alkylating agents. Mol Cell Biol 2000;20:575-582
24. Shaulian E, Schreiber M, Piu F, Beeche M, Wagner EF, Karin M. The mammalian UV response: c-Jun induction is required for exit from p53-imposed growth arrest. Cell 2000;103:897-907
25. Potapova O, Haghighi A, Bost F, Liu C, Birrer MJ, Gjerset R, Mercola D. The Jun kinase/stress-activated protein kinase pathway functions to regulate DNA repair and inhibition of the pathway sensitizes tumor cells to cisplatin. J Biol Chem 1997;272:14041-14044
26. Weitzman JB, Fiette L, Matsuo K, Yaniv M. JunD protects cells from p53-dependent senescence and apoptosis. Mol Cell 2000;6:1109-1119
27. McNulty SE, Tohidian NB, Meyskens FL Jr. RelA, p50 and inhibitor of kappa B alpha are elevated in human metastatic melanoma cells and respond aberrantly to ultraviolet light B. Pigment Cell Res 2001;14:456-465
28. Yang J, Richmond A. Constitutive IkappaB kinase activity correlates with nuclear factor-kappa B activation in human melanoma cells. Cancer Res 2001;61:4901-4909
29. Darnell JE Jr. Transcription factors as targets for cancer therapy. Nat Rev Cancer 2002;2:740-749